Actualités Nurexone Biologic Inc - NRX | Actions TSX Venture Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

Company demonstrates reliable production from multiple biological sourcesThese manufacturing advancements...

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

TORONTO and HAIFA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

Updates from NurExone: Growth Conference Presentation and Website Relaunch

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Nurexone Biologic Inc (NRX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NRX Actualités

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

Updates from NurExone: Growth Conference Presentation and Website Relaunch

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Nurexone Biologic Inc (NRX) Actualités

Nurexone Biologic Inc (NRX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NRX Actualités

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

Updates from NurExone: Growth Conference Presentation and Website Relaunch

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application